Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

Exclusion Criteria

• •Pregnant and lactating women and women of childbearing age who are unwilling to take contraceptive measures
• •Patients with prolonged QTc interval (male \> 450ms, female \> 470ms), ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI) within 1 year, congestive heart failure (CHF), and coronary heart disease with symptoms requiring drug treatment
• •B-ultrasound showed that the width of the fluid dark area in the pericardial cavity was ≥ 10 mm at the end of diastolic period
• •Patients with previous or planned organ transplantation
• •Patients receiving symptomatic treatment for early myelotoxicity within 7 days before enrollment
• •HBV nucleic acid quantitation \> 103 IU / ml
• •Patients with active bleeding
• •Patients with thrombosis, embolism, cerebral hemorrhage, cerebral infarction and other this kind of diseases or medical history
• •Patients with active infection or persistent fever within 14 days before enrollment
• •less than 6 weeks after major organ surgery
• •Abnormal liver function \[total bilirubin \> 1.5 times of the upper limit of normal value; ALT / AST \> 2.5 times of upper limit of normal value for patients without liver metastasis ; ALT / AST \> 5 times of upper limit of normal value for patients with liver metastasis \], abnormal renal function (serum creatinine \> 1.5 times of upper limit of normal value)
• •Mental disorders/Those who cannot obtain informed consent
• •Patients with drug abuse and long-term alcohol abuse that affect evaluation
• •The investigator determined not suitable to participate in this study